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AbstrAct:
It has been shown that a subset of human cancers, notably, melanoma and 
hepatocellular carcinoma (HCC) are auxotrophic for arginine (Arg), because they 
do not express argininosuccinate synthetase (ASS), the rate-limiting enzyme 
for the biosynthesis of arginine from citrulline.  These ASS-negative cancer cells 
require Arg from extracellular sources for survival.  When they are exposed to 
recombinant Arg-degrading enzymes, e.g. arginine deiminase (ADI) or arginase, 
they die because of Arg starvation; whereas normal cells which express ASS are 
able to survive.  A pegylated ADI (ADI-PEG20) has been developed for clinical 
trials for advanced melanoma and HCC; and favorable results have been obtained.   
ADI-PEG20 treatment induces autophagy in auxotrophic cancer cells leading 
to cell death.  Clinical studies in melanoma patients show that re-expression of 
ASS is associated with ADI-PEG20 resistance.  ADI-PEG20 treatment down-
regulates the expression of HIF-1α but up-regulates c-Myc in culture melanoma 
cells. Induction of ASS by ADI-PEG20 involves positive regulators c-Myc and Sp4 
and negative regulator HIF1α.  Since both HIF-1α and c-Myc play important roles 
in cancer cell energy metabolism, together these results suggest that targeted 
cancer cell metabolism through modulation of HIF-1α and c-Myc expression 
may  improve  the  efficacy  of  ADI-PEG20  in  treating    Arg  auxotrophic  tumors. 
Altered tumor metabolism as target for cancer 
chemotherapy
Dysregulation of cellular metabolism is a hallmark 
of many human malignancies. The metabolic differences 
between normal cells and tumor cells have provided 
opportunities for developing novel approaches for the 
diagnosis and treatment of cancer. The “Warburg effect” 
which describes the preferentially metabolizing glucose via 
anaerobic glycolysis instead of oxidative phosphorylation 
found in many cancers, led to the development of 
2-fluoro-2-deoxyglucose  positron  emission  tomography 
[18FDG-PET] as a valuable oncology imaging tool [1].   
Enhanced proliferative capacities found in tumor cells 
associated with aberrations of many signal transduction 
pathways resulting from genetic or epigenetic changes in 
oncogenes and/or tumor suppressor genes has led to the 
development of many targeted therapeutics for treating 
many types of malignancies. At the present time, most 
of our understanding about the dysregulated cancer 
cell metabolism remains at the “gross” physiological 
stages. As technological development advances, we 
may eventually be able to differentiate the metabolic 
differences between cancerous and normal cells at the 
single-tumor level, ultimately leading to the development 
of personalized cancer medicine.  In this review, we focus 
on the recent development of targeted therapy of a subset 
of human malignancies with altered Arg metabolism.Oncotarget 2010; 1: 246-251 247 www.impactjournals.com/oncotarget
Arginine-deficiency  and  auxotrophy  in  cancer 
cells
Arg is an intermediate metabolite in the urea cycle.   
De novo biosynthesis of Arg requires two sequential 
enzymatic steps:  argininosuccinate synthetase (ASS) 
which catalyzes the synthesis of argininosuccinate from 
L-citrulline and aspartic acid, and argininosuccinate 
lyase (ASL) which converts argininosuccinate into L-Arg 
and fumaric acid (Fig. 1); of which, ASS is the rate-
limiting enzyme.   Fumarate is an important metabolite of 
tricarboxylic acid (TCA) cycle, linking Arg metabolism 
to glucose-generated energy metabolism.   Moreover, Arg 
is involved in many other important cellular metabolic 
pathways, including the biosyntheses of polyamine, 
creatine and nitric oxide, nucleotides, proline and 
glutamate biosyntheses [2-4].
In normal cells, ASS is a ubiquitous enzyme but its 
level of expression differs among different cell types and 
can be regulated by many extracellular factors.  Expression 
of hepatic ASS can be transcriptionally regulated by cyclic 
AMP [5] and endothelial ASS expression is regulated by 
cytokines such as IL-1, TNF-a, and TGF-b1 and glutamate 
[6, 7].   Levels of ASS vary markedly in a wide spectrum of 
tumor tissues as compared with their corresponding normal 
counterparts. Elevated levels of ASS expression have 
been found in cancers of the ovary, stomach, and colon.   
By contrast, reduced or undetectable levels of ASS have 
been found in the majority of melanoma, hepatocellular 
carcinoma (HCC), mesotheliomas, renal cell carcinoma, 
and prostate cancers [8-11].  The mechanisms that control 
ASS expression in these tumor types remain elusive.  The 
ASS-negative tumors are unable to survive if the systemic 
Arg supply is depleted.  Therefore, they are auxotrophic 
for Arg. 
Figure 1:  Metabolic pathways relevant to Arg deprivation strategy using ADI-PEG20. Shown in the center are the 
coupled TCA and urea cycles. In the urea cycle, arginine is metabolized by arginase to citrulline and urea. Arginine can be metabolized into ci-
trulline and nitric oxide (NO) by nitroxide synthetase (NOS). Citrulline is converted into argininosuccinate (AS) by argininosuccinate synthetase 
(ASS).  AS is recycled back to arginine by argininosuccinate lyase. In most melanoma cells, AS is not active, therefore, arginine must come from 
an external source. Treating melanoma cells with arginine deiminase (ADI), which converts arginine to citrulline and ammonia, results in arginine 
deprivation, leading to cell death in melanoma cells. We found that ASS expression can be induced in some melanoma cells involving the interplay 
of c-Myc/HIF-1a/Sp4. The relationships of this metabolic wiring and the function of HIF-1a and c-Myc are also indicated.
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targeted therapy of Ass-negative cancers with 
arginine-degrading enzymes
Two recombinant proteins that degrade Arg have been 
under development for treating Arg auxotropic tumors:   
ADI and arginase.  ADI catabolizes the conversion of 
arginine to citrulline and ammonia; and arginase degrades 
arginine to ornithine which is then converted to citrulline 
by ornithine carbamoyl transferase (OCT), an additional 
step for arginine-to-citrulline conversion (Fig. 1). 
ADI is a bacterial enzyme secreted from Mycoplasma 
spp. into cultures. Sugimura et al [12] were the first to 
identify that ADI  from M. arginini is a lymphoblastogenesis 
inhibitory factor. Miyazaki et al [13] reported that ADI 
purified  from  Mycoplasma-derived culture medium 
potently inhibits the growth of human tumor cells.   
Takaku et al [14] described the in vivo antitumor activity 
of ADI in melanoma animal models [15, 16]. However, 
because bacterial ADI has short half-life (~ 4 hr) in the 
circulation and is highly immunogenic, Holtsberg et al 
[17] formulated a pegADI with poly(ethylene glycol) 
of molecular mass of 20,000 Daltons for clinical use, 
termed ADI-PEG20. Phase I-II clinical trial in patients 
with advanced or metastatic melanoma showed antitumor 
activities, including partial and complete responses [18].   
A 35% response rate has been seen with minimal toxicity 
[19]. Importantly, the response and stable diseases were 
only seen in patients with tumors that do not express ASS 
(L.F & NS,, unpublished clinical data). Compared with 
the poor response rates (<20%) of malignant melanoma 
to current standard treatment options [20], ADI-PEG20 
represents a novel approach for the targeted therapy of 
advanced melanoma. A phase I/IIa trial (n=19) [21] and 
a recent phase II trial [22] of ADI-PEG20 for human 
HCC showed the effectiveness of HCC treatment. In 
these studies, ADI-PEG20 treatment was well tolerated 
and effectively reduced serum Arg levels without adverse 
effects. However, antigenicity against ADI-PEG20 
eventually arose about 50 days after the treatment [22].
The antigenicity associated with ADI-PEG20 
treatment has motivated the development of recombinant 
human arginase (rhArg1) for targeting Arg auxotrophic 
tumors. While arginase is about 1000 times less potent 
as compared with ADI under physiologic condition [13], 
rhArg1 has also been under development for treating HCC 
[23]. Optimal activity for native arginase is at pH ~9.5, 
making it less active at physiological pH [24].  hArg1 
contains two coordinated Mn2+ ions at its active site. 
Replacing Mn2+ with Co2+ coordination in rhArg1 reduces 
its pH optimum to pH 7.4 and enhances its cytotoxic 
effects (~ 10-fold) to hepatoma cells in culture [25]. Thus, 
this bioengineered arginase warrants further clinical study. 
Mechanisms of cell killing in targeted therapy 
of  L-Arg  auxotrophic  cancer  cells  by  arginine-
depleting enzymes
While amino acid deprivation is known to induce 
nutritional starvation, how the  depletion of a single amino 
acid such as Arg leads to cell death is not well-understood.     
ADI-PEG20- or arginase-induced cell death in cultured 
cells usually takes 3 to 6 days.  However, early events 
such as induction of autophagy occurs can be detected 90 
min. after the start of treatment [26, 27] and can last for 
over 72 hr [28]. Autophagy is a lysosomal degradation 
pathway which involves vesicular sequestration of 
proteins or organelles into autophagasomes which then 
fuse with lysosomes and become degraded [29, 30].   
Autophagy occurs upon nutrition stress as a means to 
protect cells from apoptosis by re-cycle amino acid from 
protein degradation. In this regard, global metabolic stress 
could be detected in prostate cancer animal model 4 hr 
after ADI-PEG20 treatment as measured by 18FDG-PET 
[26].  Furthermore, activation of nutrient/energy-sensing 
pathway, which involves upregulation of AMPK/mTOR/
S6K, is accompanied with the induction of autophagy 
in ASS-negative cells treated with ADI-PEG20. Several 
studies have shown that prolonged treatment with ADI-
PEG20 in cultured cells induces apoptosis [27, 31, 32].   
The exposure time that leads to apoptosis and the extent of 
apoptosis induced by ADI-PEG20 treatments are different 
among melanoma cell lines and may be related to the 
antiapoptotic machinery in the cells [27, 33].
Mechanisms of resistance to ADI-PEG20 
mediated by the induction of argninosuccinate 
synthetase expression
One important finding in our phase I/II melanoma 
clinical trial with ADI-PEG20 was that patients who were 
initially ASS negative could become ASS positive upon 
relapse, suggesting that induction of ASS expression in 
tumors is likely to be a mechanism of ADI resistance.  To 
investigate the induction mechanism of ASS expression 
by ADI-PEG20, we used three melanoma cell lines 
A2058, SK-MEL-2, and A375. These cell lines express 
undetectable levels of ASS.  When grown in ADI-PEG20-
containing medium or Arg-free medium, induction of ASS 
expression was seen in A2058 and SK-MEL-2 cells but not 
in A375 cells.  Induction of ASS expression is associated 
with ADI-PEG20 resistance, which can be reversed 
when ASS expression is knocked down with siRNA, 
suggesting that ASS expression is correlated with ADI-
PEG20 sensitivity [34].  Further investigation revealed 
that the positive transcriptional regulator c-Myc and the 
negative transcriptional regulator HIF-1a interacting with 
the E-box element located at the promoter of the ASS gene 
(34) controls the expression of ASS.Oncotarget 2010; 1: 246-251 249 www.impactjournals.com/oncotarget
Before ADI-PEG20 treatment, HIF-1a binds to the 
E-box and silences ASS expression. Upon ADI treatment, 
HIF-1a level is rapidly downregulated (t½ ~ 45 min.) 
and c-Myc level is upregulated. c-Myc replaces HIF-1a 
binding to the promoter of ASS and transactivates the 
expression of ASS. No upregulation of c-Myc was found 
in ADI-PEG20-treated A375 cells and no switch between 
HIF-1a and c-Myc binding was found in A375 cells 
upon ADI-PEG20 treatment [34]. ADI-PEG20-resistant 
variants were found in A2058 cells and SK-MEL-2 cells 
but not in A375 cells. Thus, the inducibility of altered HIF-
1a and c-Myc expression may be a predictive signal for 
the ADI-PEG20 sensitivity of cells as well as the ultimate 
development of drug resistance. 
The observation that Arg deprivation induces up-
regulation of c-Myc but down-regulation of HIF-1a 
in some melanoma cells but not in others is intriguing.   
c-Myc plays a central role in a transcriptional network 
that regulates cell growth, differentiation, apoptosis, and 
metabolic signaling [35, 36], and it has been demonstrated 
that c-Myc depletion inhibits cell proliferation in many 
types of human tumor cells [37]. In melanoma cells, 
c-Myc depletion induces senescence reminiscent of 
normal melanocytes [38]. Likewise, HIF-1a is also 
involved in the regulation of tumor growth, angiogenesis, 
and invasion [39]. Given the recent discoveries that c-Myc 
and HIF-1a are involved in the regulation of cancer energy 
metabolism [40, 41] (Fig. 1), our finding that c-Myc and 
HIF-1a have opposite responses to ADI-PEG20 treatment 
has important implications beyond the induction of ASS 
and ADI-PEG20 sensitivity, it underscores the global 
effects on cancer cell energy metabolism as well.
conclusIons AnD FuturE 
DIrEctIons
Targeted therapy of cancers auxotrophic for Arg 
in humans using Arg-degrading enzymes, e.g. ADI-
PEG20, has been investigated at many cancer centers 
and promising results have been obtained. These types of 
cancers generally are difficult to treat with conventional 
chemotherapeutics. One important aspect of ADI-PEG20 
treatment is that patients are well-tolerated because of low 
adverse side effects. This finding provides an opportunity 
to  improve  therapeutic  efficacy  by  combining  ADI-
PEG20 with other antitumor agents. Previous studies 
have demonstrated that ADI-PEG20 treatment induces 
nutritional stress and activation of autophagy response, 
leading to cell death. Future development may combine 
the use of autophagy-targeting drugs to enhance the 
therapeutic effect of ADI-PEG20. Moreover, we have 
found that ADI-PEG20 treatment induces ASS re-
expression which is associated with the emergence of 
ADI-PEG20 resistance. We have demonstrated the roles 
of c-Myc and HIF-1a in the regulation of ASS expression, 
providing a rationale for developing c-Myc- [42] and 
HIF-1a- targeting drugs [43] to combat the evolution of 
drug resistance. Finally, it remains important to elucidate 
the underlying mechanisms by which Arg deprivation 
regulates c-Myc and HIF-1a that may have global effect 
on cancer metabolism in the Arg auxotrophic cancer cells.   
This research may eventually lead to the development of 
effective therapeutics for targeting cancer cell metabolism 
in general and Arg auxotrophic cancer in particular.  
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